← ALX ONCOLOGY HOLDINGS INC (ALXO) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
ALX ONCOLOGY HOLDINGS INC (ALXO)
Pharmaceutical Preparations · market cap $207M · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-06 (est.)
Earnings
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
ALX Oncology Holdings (ALXO) is a clinical-stage biopharma with 44 employees and a $283M market cap, built around evorpacept (ALX148), a CD47 'don't-eat-me' signal blocker in Phase 3 for gastric cancer and Phase 2 for head and neck cancer. The company carries only $32.3M in cash against a burn rate implying roughly 5 months of runway, creating acute near-term financing pressure. No revenue has been recorded historically, and cumulative R&D spend exceeds $490M over the past four reported years.
The catalyst path
- 2026-11-06 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Evorpacept (ALX148) | Phase 3 | Gastric Cancer |
| evorpacept | Phase 2 | Head and Neck Cancer |
| ALX148 | Phase 2 | Ovarian Cancer |
Price & technical context
3-month
-37.1%
6-month
-27.1%
12-month
-37.1%
52-wk range
$1.08–$2.60
vs 50-day MA
-30.1%
vs 200-day MA
-32.4%
Realized vol
89.4%
Max drawdown
-81.7%
Daily closes through 2026-10-09. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ALXO (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.